Literature DB >> 3874932

Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma.

N Jaffe, R Robertson, A Ayala, S Wallace, V Chuang, T Anzai, A Cangir, Y M Wang, T Chen.   

Abstract

A randomized two-arm study was undertaken to determine relative tumoricidal effects of intra-arterial cis-diamminedichloroplatinum II (I/A-CDP) and high-dose methotrexate with citrovorum factor rescue (MTX-CF) in the treatment of the primary tumor in patients with osteosarcoma. Responses were evaluated by clinical, radiographic, angiographic, and pathologic parameters. Fifteen patients were randomized to receive MTX-CF and 15 to I/A-CDP. In the MTX-CF arm there were four responses (three complete responses, one partial response) whereas in the I/A CDP arm there were nine responses (seven complete responses, two partial responses). Two patients who failed MTX-CF and requested alternative treatment with I/A-CDP also responded. The total I/A-CDP response was 11/17.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874932     DOI: 10.1200/JCO.1985.3.8.1101

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Evaluation of chemotherapy before limb-sparing surgery for osteosarcoma.

Authors:  T Ishida; M Takami
Journal:  Int Orthop       Date:  1992       Impact factor: 3.075

Review 2.  Methotrexate for high-grade osteosarcoma in children and young adults.

Authors:  Elvira C van Dalen; Jorrit W van As; Beatriz de Camargo
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

3.  Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy.

Authors:  H Shimizu; N Jaffe; E Kleinerman
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

4.  Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults.

Authors:  Ronald R Hugate; Ross M Wilkins; Cynthia M Kelly; Walt Madsen; Ioana Hinshaw; Anne B Camozzi
Journal:  Clin Orthop Relat Res       Date:  2008-04-25       Impact factor: 4.176

Review 5.  Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.

Authors:  Robert S Benjamin
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 6.  Treatment recommendations for osteosarcoma and adult soft tissue sarcomas.

Authors:  P Picci; S Ferrari; G Bacci; F Gherlinzoni
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 7.  Therapy for osteosarcoma: where do we go from here?

Authors:  Alexander J Chou; David S Geller; Richard Gorlick
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Role of Periostin Expression in Canine Osteosarcoma Biology and Clinical Outcome.

Authors:  Lauren N Alfino; Kai C Wilczewski-Shirai; Kathryn E Cronise; Jonathan Coy; Kristina Glapa; E J Ehrhart; Joseph B Charles; Dawn L Duval; Daniel P Regan
Journal:  Vet Pathol       Date:  2021-03-09       Impact factor: 3.157

9.  Clinico-immunological response to intratumoral versus intravenous neoadjuvant chemotherapy in advanced pediatric solid malignancies.

Authors:  Vijayendra Kumar; Nandini Ramaswami; Anand Pandey; Ram Chandra Shukla; Maloy Ranjan Sen; Shiv Prasad Sharma; Dinesh Kumar Gupta; Ajay Narayan Gangopadhyay
Journal:  Indian J Med Paediatr Oncol       Date:  2013-04

10.  Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.

Authors:  S Bernard; M C Etienne; J L Fischel; P Formento; G Milano
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.